Minute Insight: Pulsed AF Trial Of Medtronic’s PulseSelect PFA System Completes Enrollment

PULSED AF is a 500-patient pivotal trial of Medtronic’s PulseSelect PFA system for treating both paroxysmal and persistent atrial fibrillation in patients who have not responded to drugs.

Minute Insight

Medtronic announced that the US pivotal trial of its PulseSelect pulsed field ablation system has completed enrollment.

PULSED AF has enrolled 400 patients at 40 sites in the US, Canada, Europe, Australia and Japan. The patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Minute Insights

Minute Insight: Haemonetics Buys OpSens To Add Fiber-Optic Sensors For Intervention

 
• By 

Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.

Minute Insight: Best Buy Will Sell Dexcom CGM

 
• By 

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

 

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

 
• By 

Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.

More from Medtech Insight

Environmental Group Questions FDA’s Stance On PFAS In Medical Devices

 

The US FDA says PFAS used in medical devices are safe and that there’s no reason to restrict them in device production. An environmental group finds the agency’s assertion questionable.

EU4Health Boost For Orphan Devices And SMEs

 
• By 

EU4Health, the main funding instrument for EU health initiatives, has put renewed emphasis on orphan devices in its 2025 work program, published in July.

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By 

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.